Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Kelley Website

James A. Kelley, Ph.D.

Selected Publications

1)  Qian WJ, Lai CC, Kelley JA, Burke TR.
Design and Synthesis of Fmoc-Thr[PO(OH)(OPOM)] for the Preparation of Peptide Prodrugs Containing Phosphothreonine in Fully Protected Form.
Chem. Biodivers. 11: 784-91, 2014.
2)  Garcia LC, Donadío LG, Mann E, Kolusheva S, Kedei N, Lewin NE, Hill CS, Kelsey JS, Yang J, Esch TE, Santos M, Peach ML, Kelley JA, Blumberg PM, Jelinek R, Marquez VE, Comin MJ.
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
Bioorg. Med. Chem. 22: 3123-40, 2014.
3)  Smith DJ, Yap GP, Kelley JA, Schneider JP.
Enhanced stereoselectivity of a Cu(II) complex chiral auxiliary in the synthesis of Fmoc-L-?-carboxyglutamic acid.
J. Org. Chem. 76: 1513-20, 2011.
4)  Bokesch HR, Cartner LK, Fuller RW, Wilson JA, Henrich CJ, Kelley JA, Gustafson KR, McMahon JB, McKee TC.
Inhibition of ABCG2-mediated drug efflux by naphthopyrones from marine crinoids.
Bioorg. Med. Chem. Lett. 20: 3848-50, 2010.
5)  Moon HR, Siddiqui MA, Sun G, Filippov IV, Landsman NA, Lee YC, Adams KM, Barchi JJ, Deschamps JR, Nicklaus MC, Kelley JA, Marquez VE.
Using conformationally locked nucleosides to calibrate the anomeric effect: Implications for glycosyl bond stability.
Tetrahedron. 66: 6707-6717, 2010.
6)  Boswell CA, Regino CA, Baidoo KE, Wong KJ, Milenic DE, Kelley JA, Lai CC, Brechbiel MW.
A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging.
Bioorg. Med. Chem. 17: 548-52, 2009.
7)  Russ PL, Gonzalez-Moa MJ, Vu BC, Sigano DM, Kelley JA, Lai CC, Deschamps JR, Hughes SH, Marquez VE.
North- and South-Bicyclo[3.1.0]Hexene Nucleosides: The Effect of Ring Planarity on Anti-HIV Activity.
ChemMedChem. 2009.
8)  Duan D, Sigano DM, Kelley JA, Lai CC, Lewin NE, Kedei N, Peach ML, Lee J, Abeyweera TP, Rotenberg SA, Kim H, Kim YH, El Kazzouli S, Chung JU, Young HA, Young MR, Baker A, Colburn NH, Haimovitz-Friedman A, Truman JP, Parrish DA, Deschamps JR, Perry NA, Surawski RJ, Blumberg PM, Marquez VE.
Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities.
J. Med. Chem. 51: 5198-220, 2008.
9)  Boswell CA, Regino CA, Baidoo KE, Wong KJ, Bumb A, Xu H, Milenic DE, Kelley JA, Lai CC, Brechbiel MW.
Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.
Bioconjug. Chem. 19: 1476-84, 2008.
10)  Marquez VE, Sun G, Siddiqui MA, Lee YC, Barchi JJ, Filippov IV, Landsman NA, Kelley JA.
What are the consequences of freezing the anomeric effect in nucleosides?.
Nucleic Acids Symp Ser (Oxf). 543-4, 2008.
11)  Malolanarasimhan K, Kedei N, Sigano DM, Kelley JA, Lai CC, Lewin NE, Surawski RJ, Pavlyukovets VA, Garfield SH, Wincovitch S, Blumberg PM, Marquez VE.
Conformationally Constrained Analogues of Diacylglycerol (DAG). 27. Modulation of Membrane Translocation of Protein Kinase C (PKC) Isozymes alpha and delta by Diacylglycerol Lactones (DAG-lactones) Containing Rigid-Rod Acyl Groups.
J Med Chem. 50: 962-978, 2007.
12)  Jiang S, Lai CC, Kelley JA, Roller PP.
A practical synthesis of fully protected L-gamma-carboxyglutamic acid.
Tetrahedron Letters. 47: 23-25, 2006.
13)  Jiang S, Li P, Lai CC, Kelley JA, Roller PP.
Design and concise synthesis of fully protected analogues of l-gamma-carboxyglutamic acid.
J. Org. Chem. 71: 7307-14, 2006.
14)  Deng J, Kelley JA, Barchi JJ, Sanchez T, Dayam R, Pommier Y, Neamati N.
Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
Bioorg Med Chem. 14: 3785-3792, 2006.
15)  Huleihel M, Talishanisky M, Ford H, Marquez VE, Kelley JA, Johns DG, Agbaria R.
Dynamics of the antiviral activity of N-methanocarbathymidine against herpes simplex virus type 1 in cell culture.
Int J Antimicrob Agents. 25: 427-32, 2005.
16)  Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL.
Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.
Cancer Res. 65: 4673-82, 2005.
17)  Ben-Kasus T, Ben-Zvi Z, Marquez VE, Kelley JA, Agbaria R.
Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells.
Biochem Pharmacol. 70: 121-33, 2005.
18)  Malolanarasimhan K, Lai CC, Kelley JA, Iaccarino L, Reynolds D, Young HA, Marquez VE.
Synthesis and biological study of a flavone acetic acid analogue containing an azido reporting group designed as a multifunctional binding site probe.
Bioorg Med Chem. 13: 2717-22, 2005.
19)  Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA.
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.
Ann N Y Acad Sci. 1058: 246-54, 2005.
20)  Marquez VE, Barchi JJ, Kelley JA, Rao KV, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA.
Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology.
Nucleosides Nucleotides Nucleic Acids. 24: 305-18, 2005.
21)  Milanowski DJ, Gustafson KR, Kelley JA, McMahon JB.
Caulibugulones A-F, novel cytotoxic isoquinoline quinones and iminoquinones from the marine bryozoan Caulibugula intermis.
J Nat Prod. 67: 70-3, 2004.
22)  Shi ZD, Wei CQ, Lee K, Liu H, Zhang M, Araki T, Roberts LR, Worthy KM, Fisher RJ, Neel BG, Kelley JA, Yang D, Burke TR.
Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
J Med Chem. 47: 2166-9, 2004.
23)  Pompeia C, Hodge DR, Plass C, Wu YZ, Marquez VE, Kelley JA, Farrar WL.
Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line.
Cancer Res. 64: 3465-73, 2004.
24)  Marquez VE, Eritja R, Kelley JA, Vanbemmel D, Christman JK.
Potent Inhibition of HhaI DNA Methylase by the Aglycon of 2-(1H)-Pyrimidinone Riboside (Zebularine) at the GCGC Recognition Domain.
Ann N Y Acad Sci. 1002: 154-164, 2003.
25)  Marquez VE, Eritja R, Kelley JA, Vanbemmel D, Christman JK.
Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain.
Ann N Y Acad Sci. 1002: 154-64, 2003.
26)  Choi Y, Sun G, George C, Nicklaus MC, Kelley JA, Marquez VE.
Synthesis and conformational analysis of a locked analogue of carbovir built on a bicyclo[3.1.0]hex-2-enyl template.
Nucleosides Nucleotides Nucleic Acids. 22: 2077-91, 2003.
27)  Liu DG, Gao Y, Wang X, Kelley JA, Burke TR.
Enantioselective synthesis of N(alpha)-Fmoc protected (2S,3R)-3-phenylpipecolic acid. A constrained phenylalanine analogue suitably protected for solid-phase peptide synthesis.
J Org Chem. 67: 1448-52, 2002.
28)  Agbaria R, Candotti F, Kelley JA, Hao Z, Johns DG, Cooney DA, Blaese RM, Ford H.
Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells.
Biochem Biophys Res Commun. 289: 525-30, 2001.
29)  Zhang H, Ford H, Roth JS, Kelley JA.
Evaluation of a fluorogenic derivatization method for the reversed-phase HPLC analysis of 2'-beta-fluoro-2',3'-dideoxyadenosine, a new anti-AIDS drug.
J Pharm Biomed Anal. 25: 285-97, 2001.
30)  Dai F, Kelley JA, Zhang H, Malinowski N, Kavlick MF, Lietzau J, Welles L, Yarchoan R, Ford H.
Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.
Anal Biochem. 288: 52-61, 2001.
31)  Roth JS, Wang J, Kelley JA.
Determination of lodenosine and its major metabolite in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
J Mass Spectrom. 35: 1313-9, 2000.
32)  Chen IJ, Neamati N, Nicklaus MC, Orr A, Anderson L, Barchi JJ, Kelley JA, Pommier Y, MacKerell AD.
Identification of HIV-1 integrase inhibitors via three-dimensional database searching using ASV and HIV-1 integrases as targets.
Bioorg Med Chem. 8: 2385-98, 2000.
33)  Gao Y, Luo J, Yao ZJ, Guo R, Zou H, Kelley J, Voigt JH, Yang D, Burke TR.
Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
J. Med. Chem. 43: 911-20, 2000.
34)  Zhang X, Lee YK, Kelley JA, Burke TR.
Preparation of aryl isothiocyanates via protected phenylthiocarbamates and application to the synthesis of caffeic acid (4-isothiocyanato)phenyl ester.
J Org Chem. 65: 6237-40, 2000.
35)  Siddiqui MA, Driscoll JS, Abushanab E, Kelley JA, Barchi JJ, Marquez VE.
The "beta-fluorine effect" in the non-metal hydride radical deoxygenation of fluorine-containing nucleoside xanthates.
Nucleosides Nucleotides Nucleic Acids. 19: 1-12, 2000.
36)  Roth JS, McCully CM, Balis FM, Poplack DG, Kelley JA.
2'-beta-fluoro-2',3'-dideoxyadenosine, lodenosine, in rhesus monkeys: plasma and cerebrospinal fluid pharmacokinetics and urinary disposition.
Drug Metab Dispos. 27: 1128-32, 1999.
37)  Yao ZJ, King CR, Cao T, Kelley J, Milne GW, Voigt JH, Burke TR.
Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
J. Med. Chem. 42: 25-35, 1999.
38)  Lutz RJ, Kelley JA, Roth JS, Driscoll JS, Stephenson EC, Dedrick RL.
A physiological pharmacokinetic model for the anti-HIV drug, F-ddA (Proc. 10th Int. Conf. Mechanics in Med. Biol).
Ashton-Miller JA, eds.
. p. 359-362. [Meeting Proceeding]
39)  Roth JS, Ford H, Tanaka M, Mitsuya H, Kelley JA.
Determination of 2'-beta-fluoro-2',3'-dideoxyadenosine, an experimental anti-AIDS drug, in human plasma by high-performance liquid chromatography.
J Chromatogr B Biomed Sci Appl. 712: 199-210, 1998.
40)  Agbaria R, Kelley JA, Jackman J, Viola JJ, Ram Z, Oldfield E, Johns DG.
Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells.
Oncol Res. 9: 111-8, 1997.
41)  Hegedus L, Ford H, Hartman NR, Kelley JA.
Reversed-phase high-performance liquid chromatographic determination of the new antitumor agent cyclopentenyl cytosine in biological fluids.
J Chromatogr B Biomed Sci Appl. 692: 169-79, 1997.
42)  Cleaveland ES, Zaharevitz DW, Kelley JA, Paull K, Cooney DA, Ford H.
Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Biochem Biophys Res Commun. 223: 654-9, 1996.
43)  Driscoll JS, Siddiqui MA, Ford H, Kelley JA, Roth JS, Mitsuya H, Tanaka M, Marquez VE.
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.
J Med Chem. 39: 1619-25, 1996.
44)  Donzanti BA, Kelley JA, Tomaszewski JE, Roth JS, Tosca P, Placke M, Singer A, Yarrington JT, Driscoll JS.
Acute cardiotoxicity of the Anti-HIV dideoxynucleoside, F-ddA, in the rat.
Fundam Appl Toxicol. 27: 167-76, 1995.
45)  Nicklaus MC, Ford H, Hegedus L, Milne GWA, Kelley JA.
Comparative Molecular Field Analysis of Hydrophobicity Descriptors of Cytosine Nucleosides.
Quant Struct-Act Relat. 14: 335-343, 1995.
46)  Roth JS, Kelley JA.
Determination of the Anti-HIV Drug 2'-Beta-Fluoro-2',3'-Dideoxyadenosine in Biological Fluids by Reversed-Phase HPLC.
J Liq Chromatogr. 18: 441-462, 1995.
47)  Viola JJ, Agbaria R, Walbridge S, Oshiro EM, Johns DG, Kelley JA, Oldfield EH, Ram Z.
In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.
Cancer Res. 55: 1306-9, 1995.
48)  Ford H, Siddiqui MA, Driscoll JS, Marquez VE, Kelley JA, Mitsuya H, Shirasaka T.
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.
J Med Chem. 38: 1189-95, 1995.
49)  Politi PM, Xie F, Dahut W, Ford H, Kelley JA, Bastian A, Setser A, Allegra CJ, Chen AP, Hamilton JM.
Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Cancer Chemother Pharmacol. 36: 513-23, 1995.
50)  Johns DG, Ahluwalia GS, Cooney DA, Mitsuya H, Driscoll JS.
Chemistry and Anti-HIV Activity of 2'-Beta-Fluoro-2',3'-Dideoxyguanosine.
Nucleosides & Nucleotides. 13: 213-214, 1994.
51)  Ford Jr. H, Driscoll JS, Siddiqui M, Kelley JA, Mitsuya H, Shirasaka T, Johns DG, Marquez VE.
Chemistry and Anti-HIV Activity of 2'-beta-Fluoro-2',3'-dideoxyguanosine.
Nucleosides and Nucleotides. 13: 213-234, 1994.
52)  Gharehbaghi K, Paull KD, Kelley JA, Barchi JJ, Marquez VE, Cooney DA, Monks A, Scudiero D, Krohn K, Jayaram HN.
Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.
Int J Cancer. 56: 892-9, 1994.
53)  Roth JS, Kelley JA, Chun HG, Ward FT.
Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography.
J Chromatogr. 652: 149-59, 1994.
54)  Hao Z, Stowe EE, Ahluwalia G, Baker DC, Hebbler AK, Chisena C, Musser SM, Kelley JA, Perno CF, Johns DG.
Characterization of 2',3'-dideoxycytidine diphosphocholine and 2',3'-dideoxycytidine diphosphoethanolamine. Prominent phosphodiester metabolites of the anti-HIV nucleoside 2',3'-dideoxycytidine.
Drug Metab Dispos. 21: 738-44, 1993.
55)  Agbaria R, Ford H, Kelley JA, Xie F, Politi P, Grem JL, Cooney DA, Marquez VE, Allegra CJ, Johns DG.
Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.
Anal Biochem. 213: 90-6, 1993.
56)  Musser SM, Kelley JA.
Mechanism for Dehalogenation Reactions in Fast Atom Bombardment Mass Spectrometry.
Org Mass Spec. 28: 672-678, 1993.
57)  Siddiqui MA, Driscoll JS, Marquez VE, Roth JS, Shirasaka T, Mitsuya H, Barchi JJ, Kelley JA.
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
J Med Chem. 35: 2195-201, 1992.
58)  Russ PL, Hegedus L, Kelley JA, Barchi JJ, Marquez VE.
The Controlled Stereospecific Reduction of Cyclopentenyl Cytosine (CPE-C) to Carbodine and Isocarbodine.
Nucleosides & Nucleotides. 11: 351-363, 1992.
59)  Ford H, Merski CL, Kelley JA.
A Rapid Microscale Method for the Determination of Partition Coefficients by HPLC.
J Liq Chrom. 14: 3365-3386, 1991.
60)  Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ.
Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues.
J Med Chem. 34: 3280-4, 1991.
61)  Zaharko DS, Kelley JA, Tomaszewski JE, Hegedus L, Hartman NR.
Cyclopentenyl cytosine: interspecies predictions based on rodent plasma and urine kinetics.
Invest New Drugs. 9: 9-17, 1991.
62)  Murakami K, Shirasaka T, Yoshioka H, Kojima E, Aoki S, Ford H, Driscoll JS, Kelley JA, Mitsuya H.
Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.
J Med Chem. 34: 1606-12, 1991.
63)  Ward FT, Kelley JA, Roth JS, Lombardo FA, Weiss RB, Leyland-Jones B, Chun HG.
Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Cancer Res. 51: 1803-10, 1991.
64)  Barchi JJ, Marquez VE, Driscoll JS, Ford H, Mitsuya H, Shirasaka T, Aoki S, Kelley JA.
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
J Med Chem. 34: 1647-55, 1991.
65)  Marquez VE, Tseng CK, Mitsuya H, Aoki S, Kelley JA, Ford H, Roth JS, Broder S, Johns DG, Driscoll JS.
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.
J Med Chem. 33: 978-85, 1990.
66)  Fales HM, Sokoloski EA, Pannell LK, Pu QL, Klayman DL, Lin AJ, Brossi A, Kelley JA.
Comparison of mass spectral techniques using organic peroxides related to artemisinin.
Anal Chem. 62: 2494-501, 1990.
67)  Shirasaka T, Murakami K, Ford H, Kelley JA, Yoshioka H, Kojima E, Aoki S, Broder S, Mitsuya H.
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro.
Proc Natl Acad Sci U S A. 87: 9426-30, 1990.
68)  Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG.
Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates.
Cancer Res. 50: 7915-9, 1990.
69)  Surbone A, Ford H, Kelley JA, Ben-Baruch N, Thomas RV, Fine R, Cowan KH.
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Cancer Res. 50: 1220-5, 1990.
70)  Kang GJ, Cooney DA, Moyer JD, Kelley JA, Kim HY, Marquez VE, Johns DG.
Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase.
J Biol Chem. 264: 713-8, 1989.
71)  Heideman RL, Roth JS, Ford H, Kinnard RD, Litterst CL, Kelley JA.
Reverse phase HPLC determination and murine pharmacokinetics of arabinosyl-5-azacytosine.
J Liq Chrom. 12: 1613-1633, 1989.
72)  Heideman RL, Kelley JA, Packer RJ, Reaman GH, Roth JS, Balis F, Ettinger LJ, Doherty KM, Jeffries SL, Poplack DG.
A pediatric phase I and pharmacokinetic study of spirohydantoin mustard.
Cancer Res. 48: 2292-5, 1988.
73)  Moon DC, Kelley JA.
A simple desalting procedure for fast atom bombardment mass spectrometry.
Biomed Environ Mass Spectrom. 17: 229-37, 1988.
74)  Collins JM, Klecker RW, Kelley JA, Roth JS, McCully CL, Balis FM, Poplack DG.
Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid.
J Pharmacol Exp Ther. 245: 466-70, 1988.
75)  Marquez VE, Tseng CK, Kelley JA, Mitsuya H, Broder S, Roth JS, Driscoll JS.
2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV).
Biochem Pharmacol. 36: 2719-22, 1987.
76)  Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, Johns DG.
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.
Drug Metab Dispos. 15: 595-601, 1987.
77)  Kelley JA, Driscoll JS, McCormack JJ, Roth JS, Marquez VE.
Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides.
J Med Chem. 29: 2351-8, 1986.
78)  Haces A, Driscoll JS, Roth JS, Heideman RL, Kelley JA.
Spiromustine analogues. Relationships between structure, plasma stability, and antitumor activity.
J Pharm Sci. 75: 313-6, 1986.
79)  Marquez VE, Tseng CK, Gebeyehu G, Cooney DA, Ahluwalia GS, Kelley JA, Dalal M, Fuller RW, Wilson YA, Johns DG.
Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis.
J Med Chem. 29: 1726-31, 1986.
80)  Curt GA, Kelley JA, Fine RL, Huguenin PN, Roth JS, Batist G, Jenkins J, Collins JM.
A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).
Cancer Res. 45: 3359-63, 1985.
81)  Kelley JA, Tseng CK, Marquez VE.
Applications of FAB/MS in the synthesis of NAD analogues and the structure determination of oligoribonucleotides.
Adv. Mass Spectrom. Part B: 1571-1572, 1985.
82)  Litterst CL, Roth JS, Kelley JA.
Distribution, elimination, metabolism and bioavailability of hexamethylenebisacetamide in rats.
Invest New Drugs. 3: 263-72, 1985.
83)  Kelley JA, Roth JS, Litterst CL.
Gas chromatographic determination of hexamethylene bisacetamide in plasma and urine.
Anal. Lett. 18: 1043-1062, 1985.
84)  Conley BA, Sewack GF, Egorin MJ, Subramanyam B, Page JG, Grieshaber CK.
Gas-chromatographic determination of hexamethylene bisacetamide in plasma and urine.
Anal Lett Pt B - Clin Biochem. 18: 1043-1062, 1985.
85)  Zaharko DS, Covey JM, Kelley JA.
Plasma kinetics and effects of 5,6-dihydro-5-azacytidine in mice and L1210 tumor.
Invest New Drugs. 3: 35-41, 1985.
86)  Gebeyehu G, Marquez VE, Van Cott A, Cooney DA, Kelley JA, Jayaram HN, Ahluwalia GS, Dion RL, Wilson YA, Johns DG.
Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase.
J Med Chem. 28: 99-105, 1985.
87)  Huguenin PN, Kelley JA.
The synthesis of spiromustine-D8 - a general approach to octadeuterated nitrogen mustards.
J Label Compound Radiopharm. 22: 787-797, 1985.
88)  Marquez VE, Rao KVB, Silverton JV, Kelley JA.
A ring expansion approach to 1,3-diazepin-2-one nucleosides.
J Org Chem. 49: 912-919, 1984.
89)  Huguenin PN, Jayaram HN, Kelley JA.
Reverse phase HPLC determination of 5,6-dihydro-5-azacytidine in biological fluids.
J Liq Chrom. 7: 1433-1453, 1984.
90)  Rao KVB, Marquez VE, Kelley JA, Corcoran MT.
A new synthesis of 3-(beta-D-ribofuranosyl)uracil (isouridine) via the intermediacy of an O-6,5'-cyclotetrahydropyrimidinone.
J Chem Soc Perkin Trans 1. 1: 127-130, 1983.
91)  Jayaram HN, Ahluwalia GS, Dion RL, Gebeyehu G, Marquez VE, Kelley JA, Robins RK, Cooney DA, Johns DG.
Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.
Biochem Pharmacol. 32: 2633-6, 1983.
92)  Curt GA, Kelley JA, Kufta CV, Smith BH, Kornblith PL, Young RC, Collins JM.
Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
Cancer Res. 43: 6102-5, 1983.
93)  Cooney DA, Jayaram HN, Glazer RI, Kelley JA, Marquez VE, Gebeyehu G, Van Cott AC, Zwelling LA, Johns DG.
Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.
Adv Enzyme Regul. 21: 271-303, 1983.
94)  Gebeyehu G, Marquez VE, Kelley JA, Cooney DA, Jayaram HN, Johns DG.
Synthesis of thiazole-4-carboxamide adenine dinucleotide. A powerful inhibitor of IMP dehydrogenase.
J Med Chem. 26: 922-5, 1983.
95)  Lin AJ, Kelley JA, Breitman TR, Driscoll JS.
Agents with potential specificity against melanotic melanoma.
J Med Chem. 25: 501-5, 1982.
96)  Bachur NR, Collins JM, Kelley JA, Van Echo DA, Kaplan RS, Whitacre M.
Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
Clin Pharmacol Ther. 31: 650-5, 1982.
97)  Schilsky RL, Kelley JA, Ihde DC, Howser DM, Cordes RS, Young RC.
Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
Cancer Res. 42: 1582-6, 1982.
98)  Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG.
The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.
Biochem Pharmacol. 31: 2133-6, 1982.
99)  Flora KP, Cradock JC, Kelley JA.
The hydrolysis of spirohydantoin mustard.
J Pharm Sci. 71: 1206-1211, 1982.
100)  Flora KP, Cradock JC, Kelley JA.
The hydrolysis of spirohydantoin mustard.
Journal of pharmaceutical sciences. 71: 1206-11, 1982.
101)  Poochikian GK, Kelley JA.
2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone II: Isolation and characterization of degradation products.
J Pharm Sci. 70: 162-7, 1981.
102)  Kelley JA, Chong EDS.
Reverse phase HPLC determination of AZQ in biological fluids.
J Liq Chrom. 4: 1855-1867, 1981.
103)  Marquez VE, Liu PS, Kelley JA, Driscoll JS.
1,3-Diazepinones. 1. Synthesis of 5-hydroxyperhydro-1,3-diazepin-2-one.
J Org Chem. 45: 485-489, 1980.
104)  Marquez VE, Kelley JA, Driscoll JS.
1,3-Diazepinones. 2. The correct structure of squamolone as 1-carbamoyl-2-pyrrolidinone and synthesis of authentic perhydro-1,3-diazepine-2,4-dione.
J Org Chem. 45: 5308-5312, 1980.
105)  Kelley JA, Abbasi MM, Beisler JA.
Silylation-mediated oxidation of dihydropyrimidine bases and nucleosides.
Anal Biochem. 103: 203-13, 1980.
106)  Liu PS, Marquez VE, Kelley JA, Driscoll JS.
Synthesis of 1,3-diazepin-2-one nucleosides as transition state inhibitors of cytidine deaminase. 2.
J Org Chem. 45: 5225-5227, 1980.
107)  Marquez VE, Liu PS, Kelley JA, Driscoll JS, McCormack JJ.
Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase.
J Med Chem. 23: 713-5, 1980.
108)  Jayaram HN, Tyagi AK, Anandaraj S, Montgomery JA, Kelley JA, Kelley J, Adamson RH, Cooney DA.
Metabolites of alanosine, an antitumor antibiotic.
Biochem Pharmacol. 28: 3551-66, 1979.
109)  Cella JA, McGrath JP, Kelley JA, Elsoukkary O, Hilpert L.
Applications of the peracid mediated oxidation of alcohols.
J. Org. Chem. 42: 2077-2080, 1977.
110)  Beisler JA, Abbasi MM, Kelley JA, Driscoll JS.
Chemistry of antitumor triazine nucleosides. An improved synthesis of dihydro-5-azacytidine.
J. Carbohyd. Nucleos. Nucleot. 4: 281-299, 1977.
111)  Okada K, Kelley JA, Driscoll JS.
Intramolecular cyclizations leading to bridgehead bicyclics 2. 5,5-Dialkylhydantoin derivatives.
J. Hetero. Chem. 14: 511-513, 1977.
112)  Okada K, Kelley JA, Driscoll JS.
Intramolecular cyclizations leading to bridgehead bicyclics 3. 5,5-Diphenyl-2-thiohydantoin derivatives.
J. Org. Chem. 42: 2594-2597, 1977.
113)  Kazyak L, Kelley JA, Cella JA, Droege RE, Hilpert LR, Permisohn RC.
Methaqualone metabolites in human urine after therapeutic doses.
Clin Chem. 23: 2001-6, 1977.
114)  Cella JA, Kelley JA.
Preparation of spin-labeled opiates: morphine and codeine.
J Pharm Sci. 66: 1054-6, 1977.
115)  Beisler JA, Abbasi MM, Kelley JA, Driscoll JS.
Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.
J Med Chem. 20: 806-12, 1977.
116)  Marquez VE, DiParsia MT, Kelley JA.
Synthesis of pyridyl-oxadiazoles l. Characterization and thermal rearrangement of an unexpected 1,2,4-oxidiazol-5(4H)-one.
J. Hetero. Chem. 14: 1427-1429, 1977.
117)  Kelley JA, Arnold KP.
Detection of urinary Cannabis metabolites: a preliminary investigation.
J Forensic Sci. 21: 252-62, 1976.
118)  Copeland ES, Boykin ME, Kelley JA, Kullberg MP.
An electron spin resonance study of synaptosome opiate receptors. The preparation and use of a spin labeled morphine.
Biophys J. 15: 1125-39, 1975.
119)  Cella JA, Kelley JA, Kenehan EF.
Nitroxide-catalyzed oxidation of alcohols using m-chloroperbenzoic acid. A new method.
J. Org. Chem. 40: 1860-1862, 1975.
120)  Cella JA, Kelley JA, Kenehan EF.
Oxidation of nitroxides by m-chloroperbenzoic acid. Tetrahedron Lett.
Tetrahedron Lett. 2869-2872, 1975.
121)  Nau H, Forster H, Kelley JA, Biemann K.
Polypeptide sequencing by a gas chromatograph - mass spectrometer - computer system. Characterization of complex mixtures of oligopeptides as trimethylsilylated polyamino alcohols.
Biomed. Mass Spectrom. 2: 326-339, 1975.
122)  Kelley JA, Nau H, Forster H, Biemann K.
Polypeptide sequencing by a gas chromatograph - mass spectrometer - computer system. Generation and derivatization of complex mixtures of oligopeptides.
Biomed. Mass Spectrom. 2: 313-325, 1975.
123)  Cella JA, Kelley JA, Kenehan EF.
Unexpected oxidation of a nitroxide alcohol with m-chloroperbenzoic acid.
Chem. Commun. 943, 1974.
124)  Forster H, Kelley JA, Nau H, Biemann K.
McFadden WH, eds.
A new technique for the sequence determination of proteins and peptides by gas chromatography - mass spectrometry - computer analysis of complex hydrolysis mixtures. In: Techniques of combined gas chromatography - mass spectrometry: applications in organic analysis.
New York: John Wiley and Sons; 1973. p. 358-367 [Book Chapter]
125)  Nau H, Kelley JA, Biemann K.
Determination of the amino acid sequence of the C-terminal cyanogen bromide fragment of actin by computer-assisted gas chromatography--mass spectrometry.
J Am Chem Soc. 95: 7162-4, 1973.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/30/2014.